Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Blumenfeld

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Neurology and Therapy|August 5, 2023
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative ReviewAndrew M Blumenfeld, Richard B Lipton, Stephen Silberstein, et al.
Drug Safety|May 19, 2019
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL StudyPaul K Winner, Andrew M Blumenfeld, Eric J Eross, et al.
Nucleic Acids Research|November 25, 1993
Oligonucleotide circularization by template-directed chemical ligationN G Dolinnaya, M Blumenfeld, I N Merenkova, et al.
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|April 5, 2021
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction studyAbhijeet Jakate, Andrew M Blumenfeld, Ramesh Boinpally, et al.
Pain and Therapy|February 12, 2026
Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic IndicationsAndrew M Blumenfeld, Christopher Rhyne, Kenneth Martinez, et al.
Headache|February 3, 2016
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based SurveyAndrew Messali, Joanna C Sanderson, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|September 4, 2010
Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)A M Blumenfeld, S F Varon, T K Wilcox, et al.
Journal of Chromatography|August 3, 1984
Preparation of histone variants and high-mobility group proteins by reversed-phase high-performance liquid chromatographyL R Gurley, J A D'Anna, M Blumenfeld, et al.
Headache|January 18, 2023
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trialMessoud Ashina, Stewart J Tepper, Uwe Reuter, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Neurology and Therapy|August 5, 2023
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative ReviewAndrew M Blumenfeld, Richard B Lipton, Stephen Silberstein, et al.
Drug Safety|May 19, 2019
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL StudyPaul K Winner, Andrew M Blumenfeld, Eric J Eross, et al.
Nucleic Acids Research|November 25, 1993
Oligonucleotide circularization by template-directed chemical ligationN G Dolinnaya, M Blumenfeld, I N Merenkova, et al.
Neurology|November 17, 2022
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|April 5, 2021
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction studyAbhijeet Jakate, Andrew M Blumenfeld, Ramesh Boinpally, et al.
Pain and Therapy|February 12, 2026
Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic IndicationsAndrew M Blumenfeld, Christopher Rhyne, Kenneth Martinez, et al.
Headache|February 3, 2016
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based SurveyAndrew Messali, Joanna C Sanderson, Andrew M Blumenfeld, et al.
Cephalalgia : an International Journal of Headache|September 4, 2010
Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)A M Blumenfeld, S F Varon, T K Wilcox, et al.
Journal of Chromatography|August 3, 1984
Preparation of histone variants and high-mobility group proteins by reversed-phase high-performance liquid chromatographyL R Gurley, J A D'Anna, M Blumenfeld, et al.
Headache|January 18, 2023
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trialMessoud Ashina, Stewart J Tepper, Uwe Reuter, et al.
Pageof 12